Navigation Links
Faruqi & Faruqi, LLP Notifies Investors of June 4, 2012 Lead Plaintiff Deadline for the Class Action Filed Against Chelsea Therapeutics International
Date:5/29/2012

NEW YORK, May 29, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Chelsea Therapeutics International, Ltd. ("Chelsea" or the "Company") (Nasdaq: CHTP).   

(Logo:  http://photos.prnewswire.com/prnh/20120119/MM38856LOGO)

The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that:  (1) Chelsea's Northera (droxidopa) product, an orally-active synthetic precursor of norepinephrine being developed for the treatment of symptomatic neurogenic orthostatic hypotension, would not receive approval from the U.S. Food and Drug Administration; and (2) the Company's numerous statements regarding the safety and efficacy of the product, as well as reportedly positive results from Northera's clinical trials, were materially false and misleading.

On February 13, 2012, Chelsea disclosed that the Food and Drug Administration ("FDA") had raised questions regarding the efficacy, size and duration of the Company's clinical trials for the drug Northera.  Furthermore, the FDA indicated that three deaths were potentially related to the drug's trials.  In the aftermath of these disclosures, Chelsea's stock price declined by more than 37 %. Then on March 28, 2012, the Company announced that its New Drug Application for Northera was rejected by the FDA. Upon this news, Chelsea shares fell more than 28%, to close at $2.62 per share on March 29, 2012.

Request more information now by clicking here:  www.faruqilaw.com/CHTP

Take Action

If you purchased Chelsea securities between November 3, 2008 and March 28, 2012 and would like to discuss your legal rights, visit www.faruqilaw.com/CHTP.  You can also
'/>"/>

SOURCE Faruqi & Faruqi, LLP
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Faruqi & Faruqi, LLP Announces Investigation of ZELTIQ Aesthetics, Inc.
4. Faruqi & Faruqi, LLP Announces Investigation of BioSante Pharmaceuticals, Inc.
5. Faruqi & Faruqi, LLP Announces Investigation of GenVec, Inc.
6. Masimo to Present at William Blair & Company 32nd Annual Growth Stock Conference
7. Acacia Pharma Announces Excellent Phase II Results for APD421 in Post-Operative Nausea & Vomiting (PONV)
8. MicroRNA Research to Trigger Tremendous Growth in Related Tools Market, Says Frost & Sullivan
9. Frost & Sullivan Recognizes Labcyte for its Commitment to Innovation and Addressing Unmet Needs in the Liquid Handling Market
10. Oramed Pharmaceuticals to Present at the 11th National Life Science & Technology Week ILSI-BIOMED Conference; Tel Aviv, Israel, 2012
11. Medical Device Developers - Network at MD&M East Next Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014   Memorial Hermann Health System and ... announced a new partnership to provide a new level of ... centers in the greater Houston area. ... the exclusive provider of professional breast radiology services for five ... City, The Woodlands , Northeast, Southwest and ...
(Date:8/21/2014)... Aug. 21, 2014 Nektar Therapeutics (NASDAQ: ... today announced positive results from its Phase 3 ... extended half-life recombinant factor VIII (rFVIII) treatment for ... which met its primary endpoint in reducing annualized ... to the on-demand arm. Top-line results ...
(Date:8/21/2014)... , Aug. 21, 2014 The spinal column ... the human body. Signals carried to and from the brain ... skills and nervous system. Injury or ailment here can be ... with a loss of control over their body. Though back ... a person,s life, there are more options available to make ...
Breaking Medicine Technology:Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2
... CHAPEL HILL, N.C., Sept. 24 As the bio-pharmaceutical ... area of Oncology are tailoring their market education strategies ... their therapeutic area. Leading organizations have found that a ... product launch as KOLs, physicians, and payers in the ...
... WASHINGTON, Sept. 24 OrbusNeich today announced at the ... of patient enrollment in the randomized clinical trial of ... 183 patients included at sites in Asia, Australia, Europe ... this study represents a significant milestone as we look ...
Cached Medicine Technology:Effectively Educating the Marketplace to Support a Successful New Oncology Product Launch 2Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeich's Combo™ Bio-engineered Sirolimus Eluting Stent 2Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeich's Combo™ Bio-engineered Sirolimus Eluting Stent 3
(Date:8/22/2014)... autoimmune disease that affects 1 to 2 percent ... with pain, disability and joint disfigurements, but also ... and marital functioning. While many pharmacological advances help ... common. In addition, some patients avoid newer medications ... Because of this, there is interest in psychosocial ...
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 ... Dr. Sen and Dr. Samantha Pearson to help people ... and avoid corrective vision surgery by instead improving their ... prompting an investigative review. , “There’s a reason ... dollars in revenue each year—it’s because people just assume ...
(Date:8/22/2014)... 2014 Testosterone treatment lawsuits ( ... courts on behalf of men who allegedly suffered ... prescription low testosterone therapies, Bernstein Liebhard LLP reports. ... filed against Pfizer Inc. on July 31st by ... issues due to his use of Depo-Testosterone. (Case ...
(Date:8/22/2014)... 22, 2014 Mueller Sports Medicine is ... an exciting new product that provides non-drug instant relief ... active while you heal. The package includes 7 days ... new technology – it is not kinesiology tape. It’s ... PFTape™ System for Plantar Fasciitis is a breakthrough ...
(Date:8/22/2014)... 22, 2014 The improved access to ... in the developing world, has led to the decline ... of deaths due to AIDS globally. However, despite the ... of new patients becoming affected by the virus is ... undertaken by all related organisations and stakeholders, by 2015, ...
Breaking Medicine News(10 mins):Health News:Study shows cognitive-behavioral coping skills training has positive effects on rheumatoid arthritis 2Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 3
... stop trial-and-error warfarin dosing , FRIDAY, Sept. 7 (HealthDay ... anti-clotting drug warfarin should make it easier to prescribe ... , Up to this point, doctors have had to ... left patients at risk of hemorrhaging from low doses ...
... Ability to Improve Patient Care, LYNWOOD, Calif., ... Center have reached a tentative agreement on a ... increase their ability to,advocate for improved patient care, ... qualified and skilled staff. The agreement, which ...
... Concentra ("Concentra" or the,"Company"), a leader in on-site ... at the construction site of the former World,Trade ... workers a,convenient way to treat work related injuries. ... site treat construction,personnel, building partners, and other individuals ...
... AdvaMed General Counsel,Christopher White issued the following statement ... Patent Reform Act of 2007:, "The closely ... the significant bipartisan opposition to the patent reform,plan ... by,making patents easier to challenge and cheaper to ...
... Zimmer,Holdings, Inc. (NYSE: ZMH ; SWX: ZMH), ... (TSX-Venture: OSH), a leader in computer,navigation for orthopaedic ... Acquisition Co., has mailed today its offer and,circular ... takeover bid for all of ORTHOsoft,s outstanding common ...
... 650,000 hospital visits, U.S. study finds , FRIDAY, Sept. 7 (HealthDay ... both the little one and his or her family from getting ... U.S. children between six months and five years old got their ... visits due to flu could be prevented. , "We found that ...
Cached Medicine News:Health News:Researchers Find Better Way to Deliver Blood Thinner 2Health News:Workers Win Contract at St. Francis Medical Center 2Health News:Concentra Opens On-Site Medical Unit at World Trade Center Site 2Health News:Zimmer Holdings Offer and ORTHOsoft Directors' Circular Mailed to Shareholders 2Health News:Zimmer Holdings Offer and ORTHOsoft Directors' Circular Mailed to Shareholders 3Health News:Zimmer Holdings Offer and ORTHOsoft Directors' Circular Mailed to Shareholders 4Health News:Child's Flu Shot Helps Whole Family 2
Transcranial Doppler dedicated to intensive care unit and operating theatre....
The Spencer Technologies PMD 100 (TCD 100M) is the worlds first stand-alone digital transcranial doppler system....
Flagship Transcranial Doppler system with multiple channel options, multi-depth options....
The portable, cost-effective system designed for fast studies and bedside reporting. The size, features and cost make this a perfect unit for a new practice, or as a second or third unit for larger h...
Medicine Products: